FindMyKOL

Vincent Rella, MD

Basic profile

Danbury Hospital

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionDanbury, CT · NortheastSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Vincent Rella is an Oncology physician affiliated with Danbury Hospital. OpenAlex indexes 10 publications with 3,480 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
10publications

Publications indexed by OpenAlex. Counts exclude supporting files.

3,480citations

Citations across these publications.

6h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
52companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

52 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • ABBVIE INC.
    Program year20251 payment
    $27
  • ARRAY BIOPHARMA INC
    Program year20251 payment
    $24
  • ABBVIE INC.
    Program year202416 payments
    $339
All 101 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    31.5%
    Kinase inhibitor11.6%
    Imbruvica47%Jakafi34%Ibrance19%
    Part D<11 patients
    Antimetabolite7.9%
    Hydroxyurea100%
    Part D≥15 patients

    + 3 more classes in this area

  • Blood & clotting

    25%
    Factor Xa inhibitor22.8%
    Xarelto58%Eliquis42%
    Part D≥22 patients
    Vitamin K antagonist2.2%
    Warfarin Sodium100%
    Part D<11 patients
  • Nervous system

    16.1%
    Opioid Agonist4.1%
    Oxycontin56%Hydromorphone Hcl44%
    Part D<11 patients
    Gabapentinoids4%
    Gabapentin100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)14.5% facility · 85.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”